N4 Pharma PLC Change to Director Shareholding (3633A)
28 Mayo 2019 - 08:21AM
UK Regulatory
TIDMN4P
RNS Number : 3633A
N4 Pharma PLC
28 May 2019
28 May 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Change to Director Shareholding
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for vaccines and
cancer treatments, has been advised that Luke Cairns, a
non-executive director of the Company, now holds 142,660 ordinary
shares in the Company ("Ordinary Shares"), representing
approximately 0.14 per cent. of the Company's issued share
capital.
The change to Luke Cairn's shareholding is a result of a loss of
197 Ordinary Shares following the administration proceedings of
Beaufort Securities Limited ("Beaufort"), the stockbroker where Mr
Cairns formerly held his Ordinary Shares. Administrators of
Beaufort were unable to fully reconcile the Ordinary Shares that
were held in the Beaufort pooled broking account and have applied
the shortfall in Ordinary Shares across Beaufort's clients in
proportion to their entitlements to it. Mr Cairns now holds his
Ordinary Shares with a different stockbroker. Mr Cairns has
received compensation of GBP57.62 from the Financial Services
Compensation Scheme for the loss of the 197 Ordinary Shares.
Enquiries:
N4 Pharma Plc Via Scott PR
Nigel Theobald, CEO
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHXVLFLKEFFBBD
(END) Dow Jones Newswires
May 28, 2019 09:21 ET (13:21 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024